MERYEM ŞEYDA KAYA

Dr. MERYEM ŞEYDA KAYA

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2026 in Biology
Verified
Journal Article
Open access
PDF file
MKMERYEM ŞEYDA KAYA
MERYEM ŞEYDA KAYA
MEMeral Erdinc
Meral Erdinc
ZOZEYNEP ERDOGMUS OZGEN
ZEYNEP ERDOGMUS OZGEN
IKİlker Kelle
İlker Kelle
FAFesih Aktar
Fesih Aktar
MKMehmet Küçüköner
Mehmet Küçüköner
Doxorubicin (DOX) is a commonly used antineoplastic agent whose clinical use is mainly limited by its cardiotoxicity. Since necroptosis has been implicated in DOX-induced cardiotoxicity, this study investigated and compared the protective effects of dabrafenib (Dab), a RIPK3 inhibitor, and necrostatin-1 (Nec-1), a RIPK1 inhibitor, targeting two key components of the necroptotic signaling pathway. Thirty-six male Sprague–Dawley rats were divided into four groups: control, DOX, DOX+Dab, and DOX+Nec-1. Coronary perfusion pressure was assessed in isolated hearts using the Langendorff system, while serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels, cardiac malondialdehyde (MDA) levels, histopathological alterations, and the expression of necroptosis-related proteins were analyzed. DOX treatment significantly increased coronary perfusion pressure, serum CK and LDH levels, cardiac MDA levels, and RIPK1, RIPK3, and mixed lineage kinase domain-like protein (MLKL) expression and induced marked histopathological damage. Both dabrafenib and Nec-1 attenuated these alterations and histopathological damage, although the magnitude of their effects varied across the measured outcomes. No significant differences in serum CK or LDH levels were observed between the two treatment groups. Overall, our findings suggest that dabrafenib may attenuate DOX-induced cardiac injury, although its effects on necroptotic signaling remain to be established.

8 September 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Mehmet Nuri GordukMehmet Nuri Gorduk
Mehmet Nuri Gorduk
IKIlker Kelle
Ilker Kelle
MEMeral Erdinc
Meral Erdinc
MKMERYEM ŞEYDA KAYA
MERYEM ŞEYDA KAYA
Fırat AşırFırat Aşır
Fırat Aşır
Background: Colistin is increasingly being used as a last-line treatment option for multidrug-resistant Gram-negative infections; however, its clinical use remains limited due to its nephrotoxic side effects. This study investigated the potential nephroprotective effects of ethyl pyruvate (EP) and rutin hydrate (RH), alone and in combination, against colistin-induced renal damage. Methods: Forty-nine adult male Wistar albino rats were allocated into seven groups, and all agents were administered intraperitoneally once daily for seven days. On the eighth day, one kidney of each animal was perfused using a Langendorff system to measure perfusion pressure, while samples from the contralateral kidney and blood were used for biochemical, molecular, and histopathological analyses. Results: In the colistin group, urea, creatinine, total oxidant status, and perfusion pressure were significantly higher than in the control, EP, and RH groups (p < 0.05). Oxidative stress index, tissue MDA, KIM-1, caspase-3, and PUMA levels were also markedly increased. All of these parameters decreased in the treatment groups, with the lowest values for most parameters in the group receiving both EP and RH, which also showed the best-preserved renal architecture. Conclusions: These findings suggest that EP and RH may be promising adjuvant agents against colistin-induced nephrotoxicity. Combined EP and RH co-treatment showed numerically greater protection across most assessed parameters, although an overall advantage over single-agent co-treatment was not statistically established.